-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 25, Shenzhen Kangtai Biotech announced that its self-developed 13-valent pneumococcal polysaccharide conjugate vaccine has recently obtained the China National Medical Products Administration (NMPA) biological product batch issuance certificate, marking that the vaccine is officially available for sale
.
According to the press release, the vaccine is the world's first dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine, which uses two carrier proteins (tetanus toxoid/diphtheria toxoid) combined with pneumococcal capsular polysaccharide, which is different from single-carrier pneumococcal polysaccharides.
The polysaccharide conjugate vaccine can prevent the same carrier protein from competing with helper T cells and inhibiting the polysaccharide immune response
.
Phase 3 clinical trial data showed that the vaccine's antibody positive rate and geometric mean titer against 13 serotypes of pneumococcus are not inferior to similar imported products
According to estimates by the World Health Organization, 1.
6 million people die from pneumococcal infection each year, of which 460,000 are infants and young children.
Therefore, the diseases caused by them have been listed as "very high priority" diseases that require vaccine prevention
.
The “2030 Agenda for Immunization” released by WHO in April this year reiterated that the widespread use of Streptococcus pneumoniae vaccine can reduce the number of days of antibiotic use in children under 5 years of age with pneumonia by 47%, and at least the number of days of antibiotic use in the world can be reduced each year.
Reference materials:
[1] Kangtai Bio: The world's first dual-carrier 13-valent pneumonia vaccine was approved for marketing.
